Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Patients with psoriatic arthritis who received bDMARDs vs cDMARDs had a lower risk for major adverse cardiovascular events, all-cause mortality, and cardiovascular mortality. Biologic ...

We compared disease-modifying antirheumatic drug (DMARD) use for older adults with rheumatoid arthritis (RA)-related ambulatory visits from rheumatologists and primary care providers (PCPs). We ...

Please provide your email address to receive an email when new articles are posted on . Nearly all bDMARDs and tsDMARDs feature infection or malignancy warnings from the FDA or European Medicines ...

ROME — Daily baricitinib, an oral Janus kinase (JAK)1/2 inhibitor, produces rapid clinical improvement in the signs and symptoms of rheumatoid arthritis in patients with active disease who have failed ...

Traditional medications are synthesized through chemical reactions, whereas biologics are derived from and reproduced, at least partially, from living organisms. For instance, blood and plasma ...

Managing symptoms of rheumatoid arthritis may require trying different medicines to see what works best for you and your symptoms. The approval of Xeljanz has led to changes in how rheumatoid ...